LEU — LEU

One-line thesis

The only US-licensed HALEU producer sits at the mandatory processing chokepoint for every next-generation SMR and microreactor regardless of which reactor design wins -- making it picks-and-shovels for the entire domestic nuclear buildout.

Position

• T3-tranche foothold established May 2026; first-ever T3 position in the portfolio. STCG profile through ~May 2027 (hold-only window).
• Nuclear processing layer now operational in the portfolio. Scaling target band is $200-500; entry-add band is $190-205.

Thesis (detailed)

Centrus holds the only US license to produce HALEU -- high-assay low-enriched uranium (enriched to 5-20% U-235), the fuel required by most next-generation reactor and microreactor designs. This is not a competitive moat that could be replicated quickly: the Paducah, Kentucky enrichment cascade took years to license under NRC special authorization, and no other domestic entity has cleared the regulatory path to HALEU production at scale.

The structural logic is straightforward. Mike already owns the mining layer (UUUU, URG, DNN). Those miners extract natural uranium -- but natural uranium at ~0.7% U-235 cannot power an advanced reactor. It must be enriched. HALEU is the enrichment grade that unlocks the SMR thesis. Without domestic HALEU supply, every US SMR program depends on foreign enrichment (historically Russia's TENEX, now being eliminated by the Prohibiting Russian Uranium Imports Act signed 2024). LEU is the bridge from domestic mining to domestic deployment.

The DOE relationship de-risks near-term revenue. The $900M Title 17 task order and the HALEU Operations Contract (HOC, 10-year $2.7B ceiling) fund ongoing cascade operation. Centrus is already generating revenue -- not pre-revenue -- which distinguishes it from every other nuclear watchlist name except BWXT. Revenue-generating + monopoly license + government-backed demand + picks-and-shovels positioning across all reactor designs = the clearest risk/reward in the nuclear supply chain layer.

Analyst consensus is Strong Buy with a 1Y target of $278 (+31% from $213 writeup price). The upside is conservative by the standard of this portfolio; the thesis here is structural conviction and supply chain completion, not a 10x bet.

Recent catalysts (60-day rolling)

• 2026-04-00: HOC cascade operations continuation -- DOE HALEU Operations Contract (10-year, $2.7B ceiling) ongoing; quarterly milestone payments expected Q1-Q2 2026 (exact Q2 milestone date not confirmed in public sources -- check 10-Q)
• 2026-03-00: Prohibiting Russian Uranium Imports Act implementation -- Russian HALEU now sanctioned, eliminates Centrus's only credible domestic competitor for near-term US SMR fuel supply (couldn't verify exact effective enforcement date in 60-day window; policy signed May 2024, enforcement ramp ongoing)
• 2026-05-05/06: Q1 2026 earnings released (verified 2026-05-12 via stockanalysis.com). Next Q2 print ~early August 2026. Beta 1.44 (verified).
• 2026-05-13: T3 layer established -- first-ever T3 tranche position. Nuclear processing layer now operational in the portfolio.

Note: LEU has limited public news cadence outside earnings and DOE contract milestones. Absence of headlines is normal, not bearish.

Risks / What would break the thesis

• DOE contract non-renewal or scope reduction -- the HOC is the revenue foundation; any renegotiation or competitor entry via DOE authorization destroys the monopoly premium
• Uranium price collapse removes urgency for domestic fuel supply investment and pressures all upstream names including LEU
• Congressional appropriations cut to DOE nuclear programs -- HOC funding depends on annual appropriations continuity
• Competitor HALEU license approved -- if another US entity (e.g., Urenco USA, BWXT advanced enrichment) clears NRC HALEU authorization, the monopoly thesis is diluted (timeline: years, not imminent, but the structural moat is regulatory not technological)

Triggers

Entry trigger: SATISFIED 2026-05-13. Position established.

Scaling triggers (post-establishment): The T3 scaling target band is $200-500, with the next entry-add band sitting at $190-205. Non-space sector, so the position sits outside the space-cluster sector cap.

Do not trim: STCG-locked until ~May 2027. Also a structural conviction hold — the thesis is supply-chain completion, not a momentum trade.

Watch items post-entry: - HOC quarterly milestone payments (confirms DOE contract execution health) - Shares outstanding trend (dilution signal if equity raises occur) - Any new HALEU license application by competitor (monitor NRC ADAMS docket) - Q2 2026 earnings print (~early August 2026 — verify on IR calendar)

External authoritative sources

• Centrus Energy IR page
• Latest 10-K (FY2025) -- SEC EDGAR
• DOE HALEU Operations Contract announcement
• StockAnalysis LEU forecast and analyst targets
• Prohibiting Russian Uranium Imports Act -- DOE summary

Open questions / hypotheses

1. What is the exact Q2 2026 earnings date? Verify on IR calendar (~early August). Standard discipline applies even though beta 1.44 is below the >3 threshold.
2. Has the HOC cascade been running continuously, or are there operational interruptions? Q1 10-Q operating notes will confirm cascade uptime and milestone payment receipt.
3. What is the current HALEU production rate in kg/year from the Paducah cascade, and what is the nameplate capacity gap vs. projected SMR demand through 2030? This gap is the medium-term pricing catalyst.
4. Is Urenco USA (EURENCO partnership) or any other entity in active NRC pre-application for HALEU authorization? If yes, moat timeline shortens.

Decision log

• 2026-05-12: Page created.
• 2026-05-13: T3 layer established -- first-ever T3 tranche.
• 2026-05-14: Page moved from watchlist/ to stocks/. Status: watchlist → hold. Reflects held-position state.